Clinical and biological differences between clozapine responders and non-responders in treatment-resistant schizophrenia
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia (TRS). However, despite its superior efficacy, it remains underused in clinical practice because of concerns about serious adverse effects, including agranulocytosis, the need for regular blood monitoring, and uncertainty regarding treatment response. This study aims to identify clinical and biological factors associated with clozapine response, with the goal of improving and optimizing future treatment strategies for patients with TRS.